Aggressive Breast Cancer Treatments Charlotte NC

The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

Wendy Graham Brick
(704) 302-8000
1025 Morehead Medical Dr
Charlotte, NC
Specialty
Hematology / Oncology

Data Provided by:
Mark Jeffrey Mogul, MD
(704) 384-1900
1712 E 4th St
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1987

Data Provided by:
William Karnes Poston
(704) 384-4814
200 Hawthorne Lane
Charlotte, NC
Specialty
Hematology

Data Provided by:
Charles James Meakin III, MD
(704) 333-7376
200 Queens Rd Ste 400
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Cincinnati Coll Of Med, Cincinnati Oh 45267
Graduation Year: 1985
Hospital
Hospital: Gaston Memorial Hospital, Gastonia, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology; Southeast Radiation Oncology Gr

Data Provided by:
Timothy Earl Cloninger, MD
(704) 333-7376
200 Queens Rd
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1966
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Carolinas Med Ctr, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology; Sou

Data Provided by:
James Bryan Hall, MD
(704) 355-8650
PO Box 32861
Charlotte, NC
Specialties
Oncology (Cancer), Gynecological Oncology
Gender
Male
Education
Medical School: Med Univ Of Sc Coll Of Med, Charleston Sc 29425
Graduation Year: 1974

Data Provided by:
Stuart Heinrich Burri, MD
(704) 355-2273
200 Queens Rd Ste 400
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Emory Univ Sch Of Med, Atlanta Ga 30322
Graduation Year: 1995
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Carolinas Med Ctr For Mental H, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad

Data Provided by:
Richard Bernard Reiling, MD
(704) 384-9955
PO Box 33549
Charlotte, NC
Gender
Male
Education
Medical School: Harvard Med Sch, Boston Ma 02115
Graduation Year: 1967
Hospital
Hospital: Presbyterian Hospital, Charlotte, Nc

Data Provided by:
Michael Robert Haake, MD
(704) 333-7376
200 Queens Rd Ste 400
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology, Internal Medicine
Gender
Male
Education
Medical School: In Univ Sch Of Med, Indianapolis In 46202
Graduation Year: 1980
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Carolinas Med Ctr, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology; Sou

Data Provided by:
Anthony Lawrence Asher, MD
(704) 376-1605
Carolina Neurosurgery and Spine Asociates 225 Baldwin Road
Charlotte, NC
Specialties
Neurological Surgery, Surgical Oncology
Gender
Male
Education
Medical School: Wayne State Univ Sch Of Med, Detroit Mi 48201
Graduation Year: 1982

Data Provided by:
Data Provided by:

Aggressive Breast Cancer Treatments

Provided By:

TUESDAY, Aug. 25 (HealthDay News) -- The drug tamoxifen is a tried-and-true way to lower the chances of developing the most common type of recurrence among breast cancer survivors, but new research suggests it raises the risk of getting a more aggressive cancer in the healthy breast by more than four times.

However, the finding is no reason to ditch the anti-cancer drug, as even the lead researcher emphasized.

"All treatments have risks and benefits," said study author Dr. Christopher Li, an associate member of the Fred Hutchinson Cancer Research Center in Seattle. "We know that the benefits of tamoxifen treatment clearly outweigh the risks. This study adds another risk, but doesn't change the overall balance. If you consider the full balance, for most women the benefits are going to far outweigh the risks."

Li and his colleagues evaluated tamoxifen use among 1,103 breast cancer survivors from the Seattle and Puget Sound area. The women were diagnosed initially with ER-positive breast cancer, the more common and less aggressive form, between the ages of 40 and 70.

Of those women, 369 developed a second breast cancer. Nearly all of those who took the hormonal therapy after surgery or other treatment used tamoxifen for five or more years. The researchers compared those who took tamoxifen with those who did not and found the drug, which blocks estrogen (which helps tumors grow) reduced ER-positive second breast cancers but boosted the risk of ER-negative tumors, which are less common but more aggressive.

"When we looked at the different types of second cancers, tamoxifen only lowered the risk of the more common and less aggressive type of cancer, ER-positive," Li said. "It lowered that by about 60 percent. But it increases the risk of developing ER-negative, the more aggressive cancer, by fourfold."

The study is published online Aug. 25 in the journal Cancer Research.

Exactly why the tamoxifen boosts the risk of ER-negative second cancers is not known, but Li said it could be that prolonged tamoxifen use provides "a competitive advantage for the growth of ER-negative breast cancer cells."

Other experts agreed that the study is no reason to give up on tamoxifen. "The thing we have to remember is tamoxifen saves lives," said Dr. Victor Vogel, national vice president of research at the American Cancer Society.

"Even though the risk of ER-negative goes up, only with five years or more, the risk of ER-positive [second breast cancer] goes down," he said. "We shouldn't lose sight of that."

"I worry people are going to panic if they are taking this drug," said Dr. Minetta Liu, director of translational breast cancer research at the Georgetown University Medical Center, in Washington, D.C. But they should not, she said, because "it has helped a huge number of women."

More information

To learn more about tamoxifen, visit the National Cancer Institute.

Author: By Kathleen Doheny
HealthDay Reporter

SOURCES: Victor Vogel, M.D., national vice president, research, American Cancer Society, Atlanta; Christopher Li, M.D., Ph.D., associate member, Fred Hutchinson Cancer Research Center, Seattle; Minetta Liu, M.D., director, translational breast cancer research, Georgetown University Medical Center, Washington, D.C.; August 25, 2009, Cancer Research

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com